Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1–8 µM) dose- and time-dep...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Cycle
Autors principals: Prabhu, Varun V., Talekar, Mala K., Lulla, Amriti R., Kline, C. Leah B., Zhou, Lanlan, Hall, Junior, Van den Heuvel, A. Pieter J., Dicker, David T., Babar, Jawad, Grupp, Stephan A., Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Pu, Jeffrey J., Claxton, David F., Khan, Nadia, Oster, Wolfgang, Allen, Joshua E., El-Deiry, Wafik S.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927637/
https://ncbi.nlm.nih.gov/pubmed/29157092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1403689
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars